IN BRIEF: Novacyt shares sink as it faces GBP134.6 million DHSC claim

Novacyt SA - Surrey-based biotechnology group focused on clinical diagnostics - Announces that ...

Alliance News 26 April, 2022 | 11:20AM
Email Form Facebook Twitter LinkedIn RSS

Novacyt SA - Surrey-based biotechnology group focused on clinical diagnostics - Announces that the UK Department of Health & Social Care has issued a claim against it and its subsidiary Primerdesign Ltd. Claim of GBP134.6 million issued by the department is part of an ongoing contract dispute between the company and the department.

In 2020 and 2021, Novacyt provided Covid-19-testing kits to the department under a multi-million pound contract. A contract from September 2020 is in dispute.

Current stock price: 168.06 pence, down 14% on Tuesday

12-month change: down 67%

By Tom Budszus; tombudszus@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Novacyt SA 0.85 EUR 1.68 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures